ABC1 - R. Wuerstlein - Primary tumor in breast cancer and phenotype in positive lymphnodes and later disease recurrence
•
2 likes•1,168 views
Recommended
Recommended
More Related Content
What's hot
What's hot (19)
Similar to ABC1 - R. Wuerstlein - Primary tumor in breast cancer and phenotype in positive lymphnodes and later disease recurrence
Similar to ABC1 - R. Wuerstlein - Primary tumor in breast cancer and phenotype in positive lymphnodes and later disease recurrence (20)
More from European School of Oncology
More from European School of Oncology (20)
Recently uploaded
Recently uploaded (20)
ABC1 - R. Wuerstlein - Primary tumor in breast cancer and phenotype in positive lymphnodes and later disease recurrence
- 2. Tumorbiology Local disease Systemic disease Halsted Fisher Primary Tumor Lymph node lymphatic hematogenous Micrometastases Micrometastases
- 3. Significant Rate of Discordancy Between Primary Tumor and Metastases 1. Amir E, et al. J Clin Oncol. 2010;28(15S): Abstract 1007. 2. Curigliano G, et al. Ann Oncol. 2011 Feb 22 [Epub ahead of print]. 3. Karlsson E, et al. J Clin Oncol. 2010;28(15S): Abstract 1009. 4. Lindstrom LS, et al. Cancer Res. 2010;70(24 Suppl): Abstract S3-5. 2010 Studies Comparing Primary to Metastasis Amir (n~270) Prospective Reanalyzed 1 Curigliano (n~250) Retrospective Liver Only 2 Karlsson (n~470) Retrospective 3 Lindstrom (n~118-459) Retrospective 4 ER+ ER- 12% 11% 36% 26% ER- ER+ 14% 25% 22% 7% HER2- HER2+ 5% 6% nd 7% HER2+ HER2- 12% 32% nd 3%
- 8. PriMet: Concordance and Discordance P= positive, N= negative ER (%) PR (%) HER2 status (%) concordance 78.0 69.8 78.0 discordance 22.0 30.3 22.0 discordance P N 15.1 21.0 9.7 discordance N P 6.9 9.3 12.3
- 9. PriMet: Follow up for DFS and PRS n Median DFS (months) Median PRS (months) Persist. nTNBC 273 53.9 87.9 nTNBC - TNBC 36 48.2 49.2 TNBC – nTNBC (without Her2 switch) 13 25.3 21.9 TNBC – nTNBC (with Her2 switch) 15 21.3 57.2 Persist TNBC 40 16.8 29
- 11. PriMet: DFS vs. change in tumorbiology (TN status) P<0.001 (54 months) 16.8 months
- 12. PriMet: Post-recurrence survival 21.9 months * p= 0.002 87.9 months 29.0 months * estimated mean
- 17. Tumorbiology Distant recurrence (DR) breast (PT) lymphnode (LN) local therapy systemic therapy lung bone liver
- 20. Discordances from PT (Prim) to DR (Met)
Editor's Notes
- 1
- P value for test of null hypothesis ( equality of all survival distributions)